Advertisement
Phase 2 trial of zerlasiran yields first demonstration of longer effect with each dose of an siRNA
Cleveland Clinic’s Esports Medicine team weighs in on importance of multidisciplinary care
Cleveland Clinic Cognitive Battery identifies at-risk patients during Medicare annual visits
An updated review of risk factors, management and treatment considerations
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Studies reveal increased cardiac events, enhanced platelet reactivity and thrombotic potential
Reassurance from the lipid outcomes trial with the highest percentage female enrollment to date
Tech-assisted self-selection concurred with clinician-assessed eligibility in >90% of cases
OMT may be right for some with Graves’ eye disease
Surprise findings argue for caution about testosterone use in men at risk for fracture
Perserverance may depend on several specifics, including medication type, insurance coverage and medium-term weight loss
Advertisement
Advertisement